Please assess the completion status of the following clinical trial:

Trial Title: Long-term Safety Study of MP-513 in Patients With Type 2 Diabetes

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who has been receiving a stable dose and regimen of oral antihyperglycaemic agent (biguanide agent,α-glucosidase inhibitor,rapid insulin secretagogue) for diabetes over 12 weeks before administration of investigational drug~* Patients who are under dietary management and taking therapeutic exercise for diabetes over 12 weeks before administration of investigational drug~* Patients whose HbA1c is between 6.5% - 10.0%~* Patients who were not administered diabetes therapeutic drugs prohibited for concomitant use within 12 weeks before administration of investigational drug~Exclusion Criteria:~* Patients with type 1 diabetes, diabetes mellitus caused by pancreas impairment, or secondary diabetes (Cushing disease, acromegaly, etc)~* Patients who are accepting treatments of arrhythmias~* Patients with serious diabetic complications~* Patients who are habitual excessive alcohol consumption.~* Patients with severe hepatic disorder or severe renal disorder.~* Patients who are pregnant, lactating, and probably pregnant patients, and patients who can not agree to contraception

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- teneligliptin (Type: EXPERIMENTAL): teneligliptin (20 mg once daily, titrated to 40 mg if no adequate efficacy is obtained )
- teneligliptin and glinide (Type: EXPERIMENTAL): teneligliptin (20 mg once daily, titrated to 40 mg if no adequate efficacy is obtained ) plus glinide
- teneligliptin and biguanide (Type: EXPERIMENTAL): teneligliptin (20 mg once daily, titrated to 40 mg if no adequate efficacy is obtained ) plus biguanide
- teneligliptin and alpha-glucosidase inhibitor (Type: EXPERIMENTAL): teneligliptin (20 mg once daily, titrated to 40 mg if no adequate efficacy is obtained ) plus alpha-glucosidase inhibitor

Based on this trial design, predict the completion outcome and termination type (if applicable).